GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Degree of Operating Leverage

Canbridge Pharmaceuticals (HKSE:01228) Degree of Operating Leverage : -0.76 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Canbridge Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Dec. 2024 was -0.76. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Canbridge Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:

HKSE:01228's Degree of Operating Leverage is ranked better than
69.02% of 878 companies
in the Biotechnology industry
Industry Median: -0.025 vs HKSE:01228: -0.76

Canbridge Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for Canbridge Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Degree of Operating Leverage Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial 0.41 0.19 -0.45 -0.87 -0.76

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.45 -1.15 -0.87 -0.67 -0.76

Competitive Comparison of Canbridge Pharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, Canbridge Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canbridge Pharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

Canbridge Pharmaceuticals Degree of Operating Leverage Calculation

Canbridge Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Dec. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -463.407 (Dec. 2024) / -404.577 (Dec. 2023) - 1 )/( 90.862 (Dec. 2024) / 112.518 (Dec. 2023) - 1 )
=0.1454/-0.1925
=-0.76***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Canbridge Pharmaceuticals  (HKSE:01228) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Canbridge Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Canbridge Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 388 Xinping Street, Unit 18, 6th Floor, Building 21, Suzhou Industrial Park, Pilot Free Trade Zone, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.
Executives
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Xue James Qun 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Athos Capital Limited 2102 Investment manager
Moskey Matthew Love 2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela 2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund 2101 Beneficial owner
Ctx Pharma Holdings Limited 2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Kolchinsky Peter 2305 Beneficiary of a trust
Ra Capital Management, L.p. 2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines